

Vanessa Desantis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8110909/publications.pdf>

Version: 2024-02-01

29
papers

908
citations

567144

15
h-index

552653

26
g-index

32
all docs

32
docs citations

32
times ranked

1497
citing authors

#	ARTICLE	IF	CITATIONS
1	Microenvironment drug resistance in multiple myeloma: emerging new players. <i>Oncotarget</i> , 2016, 7, 60698-60711.	0.8	137
2	Bone marrow fibroblasts overexpress miRâ€27b and miRâ€214 in step with multiple myeloma progression, dependent on tumour cellâ€derived exosomes. <i>Journal of Pathology</i> , 2019, 247, 241-253.	2.1	74
3	Halting pro-survival autophagy by TGFÎ² inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 640-648.	3.3	69
4	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. <i>Cells</i> , 2020, 9, 167.	1.8	68
5	Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma. <i>Translational Oncology</i> , 2018, 11, 1350-1357.	1.7	56
6	JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. <i>Leukemia</i> , 2018, 32, 736-743.	3.3	55
7	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 997.	1.0	45
8	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 20563-20577.	0.8	45
9	MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3084.	1.8	42
10	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradationâ€Induced Mitochondrial Oxidative Stress. <i>Cancer Research</i> , 2020, 80, 2340-2354.	0.4	41
11	The role of SIRT6 in tumors. <i>Haematologica</i> , 2018, 103, 1-4.	1.7	39
12	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPInâ€ protein MP0250: a preclinical study. <i>Oncotarget</i> , 2018, 9, 13366-13381.	0.8	37
13	Diabetes and Alzheimerâ€™s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?. <i>Antioxidants</i> , 2021, 10, 1257.	2.2	29
14	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myelomaâ€Enhanced Angiogenesis: A Novel Therapeutic Target?. <i>Neoplasia</i> , 2019, 21, 93-105.	2.3	28
15	Myeloma cells act as tolerogenic antigenâ€presenting cells and induce regulatory T cells <i>in vitro</i> . <i>European Journal of Haematology</i> , 2015, 95, 65-74.	1.1	17
16	Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression. <i>Cells</i> , 2021, 10, 3185.	1.8	16
17	Myeloma cells regulate miRNA transfer from fibroblastâ€derived exosomes by expression of lncRNAs. <i>Journal of Pathology</i> , 2022, 256, 402-413.	2.1	15
18	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. <i>Journal of Clinical Medicine</i> , 2022, 11, 2513.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1926-1935.	0.8	14
20	Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1251-1258.	0.8	13
21	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. <i>Cancers</i> , 2021, 13, 3650.	1.7	13
22	Isolation and characterization of neural stem cells from dystrophic mdx mouse. <i>Experimental Cell Research</i> , 2016, 343, 190-207.	1.2	12
23	Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma. <i>American Journal of Pathology</i> , 2021, 191, 748-758.	1.9	9
24	The Landscape of lncRNAs in Multiple Myeloma: Implications in the "Hallmarks of Cancer", Clinical Perspectives and Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1963.	1.7	9
25	A Challenging Case of Visceral Leishmaniasis. <i>Reports</i> , 2022, 5, 23.	0.2	3
26	Abstract B134: Inhibition of the fibroblast growth factor system by a new FGF trap induces oxidative stress and mitochondrial apoptosis in multiple myeloma cells. , 2018, , .		0
27	Abstract C052: FGF trapping impairs multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. , 2019, , .		0
28	P-078: Prognostic value of immune cells in the multiple myeloma bone marrow microenvironment: a meta-analysis within silico and in vitro validation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S81-S82.	0.2	0
29	Antiangiogenic drugs as chemosensitizers in hematological tumors. , 2022, , 111-125.		0